Related Experiment Video
Updated: Aug 20, 2026

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
[Strontium Ranelate as a new therapeutic agent for osteoporosis]
Yasuo Imanishi1, Yoshiki Nishizawa
1Department of Metabolism, Endocrinilogy and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Abstract:
Strontium ranelate is a new chemical entity, which was recently demonstrated to reduce the fracture risk in osteoporosis patients. This unique compound has both stimulatory effect of osteoblast-mediated bone formation and inhibitory effect of osteoclast-mediated bone resorption, leading to increased bone mass.
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Osteoclasts in Bone Remodeling
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Skeletal Muscle Relaxants: Therapeutic Uses
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
